Moreover, the underuse of older, less expensive AOMs has permitted skyrocketing prescribing of new, expensive incretin mimetics for weight management (‘Obesity and GLP-1 Drugs’ 2025), which may not be necessary for or preferred by individual patients (Do et al. 2024). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.